Microbot Medical to Fully Launch LIBERTY System in 2026
Microbot Medical is continuing to generate significant market and new customer momentum as it enters 2026. In 2025, the Company met its milestones, including several pivotal achievements such as obtaining FDA 510(k) clearance for LIBERTY, the first single-use, remotely operated robotic system for peripheral endovascular procedures. The Company initiated its limited market release, quickly achieving its first customer to adopt LIBERTY for patient care. The Company is positioning itself to leverage this momentum and commercialize LIBERTY across a targeted U.S. market of 2.5 million peripheral endovascular procedures annually. This progress enables the Company to pursue and strive for the 2026 anticipated milestones listed. Anticipated 2026 Operational and Commercial Milestones Commence the Full Market Release of the LIBERTY System in Q2 2026, in conjunction with the Society of Interventional Radiology conference. Grow customer base by attracting early adopters and securing new hospitals with medium-to-high volume target procedures. Validate the LIBERTY System's significant market opportunity, with the expansion of the types of procedures that are being performed as well as the end user call point to include interventional radiologists, vascular surgeons, and interventional cardiologists. Establish commercial and operational infrastructure to support expansion into markets outside the USA, either under FDA Clearance or other regional and local regulatory approvals. Enhance the Company's core capabilities by filling cross-functional roles with the right talent to support execution and future growth. Maintain a strong presence at key medical societies and conferences, including the Society of Interventional Oncology and International Symposium on Endovascular Therapy in February, Society of Interventional Radiology in April, Global Embolization Symposium and Technologies in May and Cardiovascular and Interventional Radiological Society of Europe in September. Continue to establish pipelines to allow future growth to other interventional spaces and increase the utilization opportunity within the peripheral space. Continue collaborations with leading institutions in the areas of teleintervention and autonomous robotics and explore additional opportunities to leverage the innovative LIBERTY technology. Expand and protect the Company's global IP portfolio, which creates barriers to entry, and allows the Company to monetize its innovative technology. Leverage the strong balance sheet to fully execute its near and medium-term commercial strategy in the U.S. and globally, and to support its product development pipeline.
Trade with 70% Backtested Accuracy
Analyst Views on MBOT
About MBOT
About the author
Microbot Medical Attends Interventional Oncology Annual Meeting
- Market Release Timing: Microbot Medical is showcasing its LIBERTY® Endovascular Robotic System at the Interventional Oncology Annual Meeting from February 4-8, 2026, coinciding with its limited market release, aiming to accelerate commercial awareness and adoption through sharing physician experiences.
- First Commercial Exhibition: This conference marks the first commercial exhibition of the LIBERTY System, allowing the company to engage directly with interventional oncologists, which is expected to enhance product market traction and drive sales growth.
- Technological Innovation: LIBERTY is the only FDA-cleared single-use, remotely operated robotic system designed for peripheral endovascular procedures, aiming to improve precision and reduce radiation exposure, addressing the growing demand in interventional oncology.
- Future Market Plans: The company plans a full market release at the Interventional Radiology conference in April 2026, further showcasing LIBERTY's capabilities to promote widespread adoption in the interventional radiology field.
Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.
HC Wainwright & Co. Affirms Buy Rating for Microbot Medical, Keeps $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.
Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.
Microbot Medical Launches LIBERTY Robotic System, First Hospital Adoption Announced
- First Hospital Adoption: Emory University Hospital becomes the first to adopt the LIBERTY robotic system, marking a significant advancement in its application for peripheral vascular procedures and enhancing the hospital's leadership in interventional radiology.
- Market Release Plans: Microbot plans a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to accelerate market adoption through showcasing its innovative technology and driving growth in the medical robotics sector.
- Technological Innovation: LIBERTY is the world's first FDA-cleared single-use, remotely operated robotic system designed for peripheral interventions, aimed at improving procedural precision while reducing radiation exposure and physical strain on clinicians, thereby enhancing patient care quality.
- Strategic Collaboration: Microbot is collaborating with Emory University Hospital to establish an Endovascular Robotics Program, supporting clinicians in delivering precise care for procedures like liver tumor embolization, which further solidifies the company's strategic position in the medical robotics market.
Microbot Medical® Launches Limited Market Release of LIBERTY® Endovascular Robotic System in the U.S.
Introduction of LIBERTY®: Microbot Medical Inc. has launched the LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, focusing on a Limited Market Release (LMR) to gather insights from high-volume users.
Positive Reception: The company has received overwhelmingly positive feedback from physicians and hospital administrators, validating the demand for LIBERTY® and supporting its commercialization efforts.
Commercial Readiness: To ensure a successful LMR, Microbot has secured a third-party logistics partner and expanded its commercial leadership team, aiming for a Full Market Release (FMR) at the Society of Interventional Radiology meeting in April 2026.
Future Outlook: The company emphasizes its commitment to innovation in endovascular procedures and acknowledges potential risks associated with the commercialization of LIBERTY®, including market conditions and regulatory uncertainties.
Everything You Should Know About the Upgrade to Buy for Microbot Medical (MBOT) Rating
Zacks Rank Upgrade: Microbot Medical Inc. (MBOT) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.
Earnings Estimate Revisions: The Zacks Consensus Estimate for Microbot Medical has risen by 6.3% over the past three months, reflecting an improvement in the company's underlying business and suggesting potential for near-term stock price growth.
Microbot Medical Attends Interventional Oncology Annual Meeting
- Market Release Timing: Microbot Medical is showcasing its LIBERTY® Endovascular Robotic System at the Interventional Oncology Annual Meeting from February 4-8, 2026, coinciding with its limited market release, aiming to accelerate commercial awareness and adoption through sharing physician experiences.
- First Commercial Exhibition: This conference marks the first commercial exhibition of the LIBERTY System, allowing the company to engage directly with interventional oncologists, which is expected to enhance product market traction and drive sales growth.
- Technological Innovation: LIBERTY is the only FDA-cleared single-use, remotely operated robotic system designed for peripheral endovascular procedures, aiming to improve precision and reduce radiation exposure, addressing the growing demand in interventional oncology.
- Future Market Plans: The company plans a full market release at the Interventional Radiology conference in April 2026, further showcasing LIBERTY's capabilities to promote widespread adoption in the interventional radiology field.
Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.
HC Wainwright & Co. Affirms Buy Rating for Microbot Medical, Keeps $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.
Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.
Microbot Medical Launches LIBERTY Robotic System, First Hospital Adoption Announced
- First Hospital Adoption: Emory University Hospital becomes the first to adopt the LIBERTY robotic system, marking a significant advancement in its application for peripheral vascular procedures and enhancing the hospital's leadership in interventional radiology.
- Market Release Plans: Microbot plans a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to accelerate market adoption through showcasing its innovative technology and driving growth in the medical robotics sector.
- Technological Innovation: LIBERTY is the world's first FDA-cleared single-use, remotely operated robotic system designed for peripheral interventions, aimed at improving procedural precision while reducing radiation exposure and physical strain on clinicians, thereby enhancing patient care quality.
- Strategic Collaboration: Microbot is collaborating with Emory University Hospital to establish an Endovascular Robotics Program, supporting clinicians in delivering precise care for procedures like liver tumor embolization, which further solidifies the company's strategic position in the medical robotics market.
Microbot Medical® Launches Limited Market Release of LIBERTY® Endovascular Robotic System in the U.S.
Introduction of LIBERTY®: Microbot Medical Inc. has launched the LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, focusing on a Limited Market Release (LMR) to gather insights from high-volume users.
Positive Reception: The company has received overwhelmingly positive feedback from physicians and hospital administrators, validating the demand for LIBERTY® and supporting its commercialization efforts.
Commercial Readiness: To ensure a successful LMR, Microbot has secured a third-party logistics partner and expanded its commercial leadership team, aiming for a Full Market Release (FMR) at the Society of Interventional Radiology meeting in April 2026.
Future Outlook: The company emphasizes its commitment to innovation in endovascular procedures and acknowledges potential risks associated with the commercialization of LIBERTY®, including market conditions and regulatory uncertainties.
Everything You Should Know About the Upgrade to Buy for Microbot Medical (MBOT) Rating
Zacks Rank Upgrade: Microbot Medical Inc. (MBOT) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.
Earnings Estimate Revisions: The Zacks Consensus Estimate for Microbot Medical has risen by 6.3% over the past three months, reflecting an improvement in the company's underlying business and suggesting potential for near-term stock price growth.
